Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):141–148. doi: 10.1097/QAI.0000000000001474

Table 1.

Descriptive characteristics of the study population, according to the reason for a gap in care (“true gap,” which was a confirmed loss to clinic, or “unknown”) at the clinic of enrollment, and overall (N=30,931).

Reason for gap in care
True Gap (Total N=24, 093)
N (%)
Unknown (Total N=6,838)
N (%)
Overall (Total N=30,931)
N (%)
Age at beginning of gap in care (years)
18–24.9 1978 (8.2) 1037 (15.2) 3015 (9.7)
25–34.9 8531 (35.4) 2831 (41.4) 11362 (36.7)
35–44.9 8266 (34.3) 1920 (28.1) 10186 (32.9)
45+ 5318 (22.1) 1050 (15.4) 6368 (20.6)
Gender
Male 7732 (32.1) 2108 (30.8) 9840 (31.8)
Female & non-pregnant 14570 (60.5) 4210 (61.6) 18780 (60.7)
Female & pregnant at enrolment 1791 (7.4) 520 (7.6) 2311 (7.5)
On ART before gap in care
No 9634 (40.0) 4325 (63.2) 13959 (45.1)
Yes 14459 (60.0) 2513 (36.8) 16972 (54.9)
HIV status disclosed
No 7818 (34.6) 2481 (39.4) 10299 (35.6)
Yes 14779 (65.4) 3820 (60.6) 18599 (64.4)
CD4 at enrollment
<350 15330 (65.5) 3482 (57.5) 18812 (63.8)
350+ 8078 (34.5) 2575 (42.5) 10653 (36.2)
WHO stage 3/4 at enrollment
½ 13098 (62.9) 3233 (63.2) 16331 (63.0)
¾ 7712 (37.1) 1882 (36.8) 9594 (37.0)
Travel time to clinic
0–60 minutes 14996 (64.2) 4293 (65.8) 19289 (64.6)
>60 minutes 8348 (35.8) 2233 (34.2) 10581 (35.4)
Successful outreach within 8 days
No 9915 (41.2) 6838 (100.0) 16753 (54.2)
Yes 14178 (58.8) 0 (0.0) 14178 (45.8)
Return to care after the 1st gap
No 3569 (14.8) 6838 (100.0) 10407 (33.6)
Yes 20524 (85.2) 0 (0.0) 20524 (66.4)
Median (IQR) Median (IQR) Median (IQR)

Age at beginning of gap (years) 36.5 (30.5, 43.8) 33.3 (27.4, 40.8) 35.9 (29.8, 43.2)
CD4 at enrollment 246 (113, 431) 293 (137, 482) 255 (117, 444)